Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus ...

Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity ...

Women with systemic lupus erythematosus who receive immunosuppressive therapy show a higher prevalence of cervical lesions and cervical human papillomavirus infection than immunocompetent women.

Systemic lupus erythematosus (SLE) involves ongoing inflammation, tissue damage from immune complexes, and incomplete immune resolution. A key factor ...

The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing treatment complexity, intensifying competition among advanced therapies, and a robust ...

SSc and SLE are chronic autoimmune diseases with distinct and overlapping characteristics, including fibrosis in SSc and systemic inflammation in SLE. RNA sequencing identified differentially ...

A retrospective study compared cardiovascular risks among patients with SLE who did and did not develop lupus nephritis and/or antiphospholipid antibody-positivity over time.

Objective To investigate the relationship between adverse childhood experiences (ACEs) and health outcomes in childhood-onset ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License ...

Filing acceptance based on Phase III ALLEGORY data for Gazyva showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE)If approved, ...